Get to know and reach out to the experts at Profil.

Short Bio

Leona has profound scientific and medical expertise in the field of obesity, diabetes, and metabolism. She has a strong background of research in both academic and industry environments with particular know-how in in basic science in molecular endocrinology and energy metabolism as well as translational clinical research and early-phase clinical development for obesity and diabetes.

Additionally, she is experienced in the development process of bioactive food compounds for nutraceutical applications. Prof. Dr. Plum-Mörschel is an active academic lecturer and member in both diabetes- and endocrinology-related professional scientific societies. In combination with the unique experience in diabetes and cardio-metabolic research, the expertise in nutritional sciences and the availability of a metabolic ward at Profil, the Obesity & Prediabetes Department facilitates the design and conduct of intelligent and comprehensive clinical trials focusing on body adiposity, either as a primary focus or as a means to improve glycemic control, metabolic disease risk, or other significant comorbidities.

Publications

Here are Leona's recent publications:

• Westergaard L, Alifrangis L, Buckley ST, Coester HV, Klitgaard T, Kristensen NR, Nishimura E, Nørgreen L, Rocha TMP, Steensgaard DB, Vegge A, Plum-Mörschel L. Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus. Clin Drug Investig. 2024 Nov;44(11):849-861. doi: 10.1007/s40261-024-01405-8. Epub 2024 Nov 3. PMID: 39488821; PMCID: PMC11564230. 
• Leohr J, Dellva MA, LaBell E, Coutant DE, Arrubla J, Plum-Mörschel L, Zijlstra E, Fukuda T, Hardy T. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Obes Metab. 2024 Jan;26(1):215-223. doi: 10.1111/dom.15307. Epub 2023 Oct 9. PMID: 37814517. 
• Chen W, Lu J, Plum-Mörschel L, Andersen G, Zijlstra E, He A, Xie T, Li L, Hao C, Gan Z, Heise T. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins. Diabetes Obes Metab. 2023 Dec;25(12):3817-3825. doi: 10.1111/dom.15281. Epub 2023 Sep 21. PMID: 37735841. 
• Handy C, Chaudhry MS, Qureshi MRA, Love B, Shillingford J, Plum-Mörschel L, Zijlstra E. Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study. J Diabetes Sci Technol. 2024 Nov;18(6):1408-1415. doi: 10.1177/19322968231170242. Epub 2023 Apr 27. PMID: 37102600; PMCID: PMC11529082. 
• Heise T, Plum-Mörschel L, Zijlstra E. Oral insulin: A history of ambition, failure and data torturing. Diabetes Obes Metab. 2023 Apr;25(4):940-942. doi: 10.1111/dom.14984. Epub 2023 Feb 8. PMID: 36692379. 
• Heller S, Battelino T, Bailey TS, Pieber TR, Hövelmann U, Plum-Mörschel L, Melgaard AE, Aronson R, DiMeglio LA, Johansen T, Danne T. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes Obes Metab. 2023 May;25(5):1351-1360. doi: 10.1111/dom.14987. Epub 2023 Feb 14. PMID: 36692230. 
• Plum-Mörschel L, Andersen LR, Hansen S, Hövelmann U, Krawietz P, Kristensen NR, Lehrskov LL, Haahr H. Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus. Clin Drug Investig. 2023 Feb;43(2):119-127. doi: 10.1007/s40261-022-01243-6. Epub 2023 Jan 11. PMID: 36631720; PMCID: PMC9902323. 
• Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes Metab. 2023 Apr;25(4):1011-1023. doi: 10.1111/dom.14948. Epub 2023 Jan 30. PMID: 36527386. 
• Bianzano S, Nordaby M, Plum-Mörschel L, Peil B, Heise T. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. Diabetes Obes Metab. 2023 Mar;25(3):832-843. doi: 10.1111/dom.14932. Epub 2022 Dec 22. PMID: 36478142; PMCID: PMC10107759. 
• Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. PMID: 35589611; PMCID: PMC9543887. 
• Meier JJ, Quast DR, Nauck MA, Schenker N, Deacon CF, Holst JJ, Plum-Mörschel L, Kapitza C. Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes Obes Metab. 2022 May;24(5):806-815. doi: 10.1111/dom.14636. Epub 2022 Jan 21. PMID: 34984794. 
• Plum-Mörschel L, Singh G, Murugesan SMN, Marwah A, Panda J, Loganathan S, Athalye SN. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study. Diabetes Obes Metab. 2022 Apr;24(4):713-721. doi: 10.1111/dom.14635. Epub 2022 Jan 28. PMID: 34981621; PMCID: PMC9303355. 
• Kazda C, Leohr J, Liu R, Reddy S, Dellva MA, Loh MT, Hardy T, Plum-Mörschel L. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes Obes Metab. 2022 Feb;24(2):196-203. doi: 10.1111/dom.14563. Epub 2021 Oct 24. PMID: 34595812; PMCID: PMC9297852. 

• Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Palle MS, Vogl T, Loomba R, Plum-Mörschel L.
  Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
  ALIMENT PHARMACOL THER 2021 Sep 27. doi:10.1111/apt.16608. Online ahead of print.

• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R.
  Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. 

• Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
  Pharmacokinetic and glucodynamic responses of ultra rapid lispro vs lispro across a clinically relevant range of subcutaneous doses in healthy subjects.
  Clin Ther 42: 1762-1777, 2020

• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol 2020 Oct 30. doi: 10.1111/bcp.14632. Online ahead of print
• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  Adv Ther 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print

• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print

• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study.
  DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print

Browse Profil's list of publications to see our other publications.

Selected Achievements and Work Experience